Cel-Sci Corporation - CVM

Cel-Sci Corporation (CVM)
http://www.cel-sci.com/
Coverage: June 13, 2009 - December 13, 2009
Featured: June 13, 2009

The WHO (I'm not kidding- World Health Organization) has officially declared the Swine Flu as a world wide pandemic. This past week, the WHO raised the Swine Flu to "Phase 6", it's highest level for global risk. The Phase 6 alert does not mean the severity is increasing- it means the spread is more global. The Phase 6 ranking opens the door to accelerated production and research on a number of possible therapies and vaccines.

One company getting major recognition for a possible therapy is AMEX listed Cel-Sci (AMEX: CVM), a stock I have been following on and off for many years. Last week, CVM announced its L.E.A.P.S (Ligand Epitope Antigen Presentation System) technology, could represent an immune based therapy for swine flu, and had shown promise. At the Naval Medical Research Center in Silver Spring, MD, L.E.A.P.S has demonstrated an ability to enhance the body's natural protection against many different kinds of diseases. The Navy is focused on using the therapy to treat Malaria. This past week, Cel-Sci announced it was developing an immune based treatment for the Swine Flu, and the stock went absolutely ballistic.

Cel-Sci traded 32 million shares in one day last week, the highest volume in its more than 20 years of being a publicly traded company under the ticker CVM. CVM also surged from about $.25 to $.80 in one day. Pretty crazy.

Latest Newsletter Editions

spacer
Sat, Jan 16, 2010 @ 09:01 am
The Biotech Buzz Rerun I looked for some recent small stock biotech winners. Check out the action in ECTE of late. $1.30 to $2.20 this month on increasing volume as the stock climbs the charts. There's a lot of action in these small biotechs right now. Do you believe in reincarnation? In the stock market...
Wed, Jan 13, 2010 @ 11:01 am
The China/Biotech Buzz It's been a very strong week for my China ideas, with several of the top choices delivering strong news and making new all time highs this week. Review and comments on the hot China ideas below. Biotechs are buzzing right now, and a great number of small cap/biotech stocks are...
Wed, Dec 2, 2009 @ 08:12 am
Coming Attractions You might recall an edition I published about a month ago suggesting it was time to step back, take a look at every idea, and set some cash aside to get past tax selling season and into December. The time has come. I suspect December will be a good month in the markets. Small stocks...
Mon, Nov 9, 2009 @ 02:11 pm
You Asked For It; You'll Get It As expected, lots of you read about my Interclick (NASDAQ: ICLK) idea over the weekend, and sent me the same comment: Why didn't you tell us about this one back in May when it was still under $1 on the Bulletin Board? Point taken- after all, isn't that the goal of investing...
Sat, Oct 10, 2009 @ 04:10 pm
A Couple More Updates: Cel-Sci (AMEX: CVM) and CalAmp (NASDAQ: CAMP) There's lots more action to cover from this past week, so let's get to two more of the actively traded ideas I have shared of late. Cel-Sci (NYSE AMEX: CVM): The Squawking and Finger Pointing Was Inevitable CVM, one of the hottest...

Click Here For More Newsletters on CVM

spacer

Latest Blog Entries

spacer

Quote Data

spacer
Last Trade: 0.96 Bid: 0.9500
Last Size: 600 Ask: 1.0600
Trade Time: 4:00pm Bid x Ask Size: 5000x2000
Change: down arrow -0.0800 (-7.69%) Day's Range: 0.95 - 1.09
Prev Close: 1.0400 52wk Range: 0.54 - 1.32
Open: 1.0500 P/E (ttm): N/A
Volume: 815,049 EPS (ttm): -0.46
spacer [Chart]

Business Summary

spacer
CEL-SCI Corporation, a biotechnology company, engages in research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The company’s primary product Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines under phase II clinical trail for the treatment of cancer. It also develops CEL-1000 peptide product with its Ligand Epitope Antigen Presentation System technology which is under preclinical stage for the protection/treatment of animals against herpes, malaria, viral encephalitis, and cancer. The company markets its products to cancer centers, physicians, and clinics involved in immunotherapy. CEL-SCI was founded in 1983 and is based in Vienna, Virginia.

Disclosure

spacer
TGR Group LLC, an affiliate of MarketByte LLC, has been paid a fee of 100,000 newly issued restricted shares by Cel-Sci Corporation, for coverage of the Company.

Recent News Headlines

spacer
CEL-SCI is a Rare Value Opportunity in Cancer Immunotherapy Stocks
Thu, 23 Apr 2015 13:00:00 GMT
[Accesswire] - NEW YORK, NY / ACCESSWIRE / April 23, 2015 / Cancer immunotherapy is scorching hot. At no time in medical history has a new cancer treatment been so widely researched and highly paid for. Over the last ...
NEW STORY UK's Aintree University Hospital Joins CEL-SCI's Phase III Head and Neck Cancer Trial
Mon, 13 Apr 2015 21:24:23 GMT
[at noodls] - UK's AINTREE UNIVERSITY HOSPITAL JOINS CEL-SCI'S PHASE III HEAD AND NECK CANCER TRIAL Vienna, VA, April 13, 2015 -- CEL-SCI Corporation (NYSE MKT: CVM) today announced that Aintree University Hospital, ...
UK’s Aintree University Hospital Joins CEL-SCI’s Phase III Head and Neck Cancer Trial
Mon, 13 Apr 2015 12:38:00 GMT
UK’s Aintree University Hospital Joins CEL-SCI’s Phase III Head and Neck Cancer Trial
Mon, 13 Apr 2015 12:38:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that Aintree University Hospital, in Liverpool, England, has become a clinical site for the Company’s global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* .
CEL SCI CORP Files SEC form 8-K, Other Events
Thu, 02 Apr 2015 20:39:45 GMT
NEW STORY CEL-SCI Reports 3rd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
Wed, 01 Apr 2015 13:38:55 GMT
[at noodls] - CEL-SCI REPORTS 3rd CONSECUTIVE MONTH OF RECORD PATIENT ENROLLMENT IN 2015 FOR ITS PHASE III HEAD AND NECK CANCER TRIAL Over 400 patients enrolled in trial as of March 31st Vienna, VA, April 1, 2015 -- ...
CEL-SCI Reports 3rd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
Wed, 01 Apr 2015 12:45:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that in March it has enrolled 29 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* .
CEL SCI CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
Wed, 18 Mar 2015 20:31:20 GMT
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
Thu, 12 Mar 2015 12:52:00 GMT
[Accesswire] - BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. ...
CEL-SCI Corp (CVM) Falls: Stock Goes Down 7% - Tale of the Tape
Mon, 09 Mar 2015 13:03:01 GMT
CEL-SCI Corporation (CVM) in Focus: Stock Jumps 5.6% - Tale of the Tape
Wed, 04 Mar 2015 14:21:02 GMT
NEW STORY CEL-SCI Completes Key Milestone with Clearance to Conduct Phase III Trial in 21 Countries
Tue, 03 Mar 2015 15:14:01 GMT
[at noodls] - CEL-SCI COMPLETES KEY MILESTONE WITH CLEARANCE TO CONDUCT PHASE III TRIAL IN 21 COUNTRIES Belarus is 21st country to clear CEL-SCI's trial for patient enrollment Vienna, VA, February 27, 2015 -- CEL-SCI ...
NEW STORY CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
Tue, 03 Mar 2015 15:14:01 GMT
[at noodls] - CEL-SCI REPORTS 2nd CONSECUTIVE MONTH OF RECORD PATIENT ENROLLMENT IN 2015 FOR ITS PHASE III HEAD AND NECK CANCER TRIAL Enrolls 25 patients during the month of February Vienna, VA, March 3, 2015 -- CEL-SCI ...
CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
Tue, 03 Mar 2015 13:15:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that in February it has enrolled 25 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* .
Coverage initiated on CEL-SCI Corp by Dawson James
Mon, 02 Mar 2015 14:20:22 GMT
Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels
Mon, 02 Mar 2015 13:35:00 GMT
[PR Newswire] - Cutting-edge biotech & nutraceutical products, science-based pharmaceuticals and healthy whole food nutrition products reveal technological advancements are in growing demand for treatments of lifestyle related disorders such as hyperglycemia, obesity, insulin level issues and other serious illnesses and health concerns. Nutraceutical and Biotech Companies in focus today are: RiceBran Technologies (RIBT), Amira Nature Foods Ltd. (ANFI), CEL-SCI Corporation (CVM), Mondelez International, Inc. (MDLZ) and Cyclacel Pharmaceuticals, Inc. (CYCC).
NEW STORY CEL-SCI to Participate in Ascendiant's Quarterly Management Discussion Series Today, Friday February 20 at 11 AM Eastern Time
Fri, 27 Feb 2015 20:45:28 GMT
[at noodls] - CEL-SCI TO PARTICIPATE IN ASCENDIANT'S QUARTERLY MANAGEMENT DISCUSSION SERIES TODAY, FRIDAY FEBRUARY 20 AT 11 AM EASTERN TIME Vienna, VA, February 20, 2015 -- CEL-SCI Corporation (NYSE MKT: CVM), a late ...
CEL-SCI Completes Key Milestone with Clearance to Conduct Phase III Trial in 21 Countries
Fri, 27 Feb 2015 20:22:00 GMT
[Business Wire] - CEL-SCI Corporation today announced the Ministry of Health of the Republic of Belarus has cleared the Company to commence patient enrollment for its Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine* .
CEL-SCI Corporation (NYSE MKT: CVM), Arguably the Most Undervalued Phase III Biotech, is Featured in Flaherty Special Situation Newsletter
Fri, 27 Feb 2015 13:19:00 GMT
[Accesswire] - WEST HARRISON, NY / ACCESSWIRE / February 27, 2015 / CEL-SCI Corporation (NYSE MKT: CVM), arguably the most undervalued Phase III biotech, is featured in the February 24th issue of Flaherty Special Situation ...
CEL-SCI Corp.'s CEO Geert Kersten Interviewed by The Life Sciences Report
Mon, 23 Feb 2015 14:15:00 GMT
[Marketwired] - Control and manipulation of the immune system is the underlying basis behind vaccinations in the fight against dangerous infectious diseases, but using immunotherapies to treat cancers and autoimmune disorders ...